Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major

Pediatric Endocrinology Reviews

Volumn 6, Issue SUPPL. 1, 2008, Pages 144-148

  Skordis, Nicos ^a   Ioannou, Yiannis S ^a   Kyriakou, Andreas ^a   Savva, Savvas C ^b   Efstathiou, Elisavet ^a   Savvides, Irene ^a   Christou, Soteroulla ^a  

^a Archbishop Makarios III Hospital   (Cyprus)

^b Research and Education Institute of Child Health   (Cyprus)

Author keywords

Alendronate; Bisphosphonates; BMD; Osteoporosis; Pamidronate; Thalassaemia

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCIUM CARBONATE; DEFERIPRONE; DEFEROXAMINE; ESTROGEN; PAMIDRONIC ACID; PROGESTERONE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD TRANSFUSION; BONE DENSITY; BONE MASS; BONE MINERAL; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GREECE; HUMAN; HYPOGONADISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; RETROSPECTIVE STUDY; THALASSEMIA MAJOR;

ABSORPTIOMETRY, PHOTON; ADULT; ALENDRONATE; BETA-THALASSEMIA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 58149481346     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;123:730-737
2. Anapliotou M.L, Kastanias I.T, Psara P, Evangelou E.A, Liparaki M., Dimitriou, P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol 1995;42:279-287
3. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev 2007;5:642-648
4. Salama OS, Al-Tonbary YA, Shahin RA, Eldeen OA. Unbalanced bone turnover in children with beta-thalassemia. Hematol 2006;11:197-202
5. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D. Bone resorption is increased in young adults with thalassemia major. Br J Haematol 2001;112:36-41
6. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. British Journal of Haematology 2000;111:902-907
7. Lasco A, Cannavò S, Gaudio A, Morabito N, Trifiletti A, Di Cesare E, Basile G, Nicita-Mauro V, Frisina N. Raloxifene and pituitary secretion in post-menopausal women. J Endocrinol Invest 2002;25(Suppl 10):95-96
8. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N. Osteoprotegerin and RANKL in the pathogenesis of thalassemiainduced osteoporosis: new pieces of the puzzle. Journal of Bone and Mineral Research 2004;19:722-727
9. Voskaridou E, Terpos E, Spina G, Patermos J, Rahemtulla A, Loutradi A, Loukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003;123:730-737
10. Suda T, Nakamura L, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone and Miner Res 1997;12:869-879
11. Fleisch H. Bisphosphonates: mechanisms of action. Endocrinol Rev 1998;19:80-100
12. Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clinical Therapeutics 1999;21:1025-1044
13. Graham R, Russell G. Bisphosphonates: Mode of Action and Pharmacology. Pediatrics 2007;119:S150-S162
14. Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, van der Wee-Pals LJA. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1, 1-bisphosphonate (APD) in rats. Calcif Tissue Int 1980;32:145-157
15. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700
16. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16:104-112
17. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EK, Roos JC, Valentijn RM, Zwinderman AH. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002;17:1057-1064
18. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003;123:730-737
19. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443
20. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541
21. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Torino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Aledronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199
22. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-1480
23. Saag KG, Emkey K, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG.. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299
24. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;134:604-610
25. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N. Bisphosphonates in the Treatment of Thalassemia-induced Osteoporosis. Osteoporosis Int 2002;13:644-649
26. Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE. Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 2003;21:402-408
27. Wonke B. Clinical management in β-thalassemia major. Semin Hematol 2001;38:350-359
28. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E. Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 2006;91:1193-1202
29. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou S, Athanasiou-Metaxa M, Harsoulis F. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 2007;86:23-30